A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to find out what effects a new drug, palbociclib, has on
prostate cancer and will look at the side effects of treatment with palbociclib. The
researchers doing this study are also interested in looking for markers that may help
predict which patients are most likely to be helped by palbociclib and to see how the cancer
cells respond to palbociclib.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society